Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|DRUG: Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|DRUG: Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Sponsor: R-Pharm